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as (CD95, APO-1, TNFRSF6) is a TNF receptor super-
family member that directly triggers apoptosis and
contributes to the maintenance of lymphocyte homeo-
stasis and prevention of autoimmunity. Although FADD
and caspase-8 have been identiﬁed as key intracellular
mediators of Fas signaling, it is not clear how recruitment
of these proteins to the Fas death domain leads to activation
of caspase-8 in the receptor signaling complex. We have
used high-resolution confocal microscopy and live cell
imaging to study the sequelae of early events in Fas
F
 
signaling. These studies have revealed a new stage of Fas
signaling in which receptor ligation leads to the formation
of surface receptor oligomers that we term signaling
protein oligomerization transduction structures (SPOTS).
Formation of SPOTS depends on the presence of an intact
Fas death domain and FADD but is independent of cas-
pase activity. Analysis of cells expressing Fas mutations
from patients with the autoimmune lymphoproliferative
syndrome (ALPS) reveals that formation of SPOTS can be
disrupted by distinct mechanisms in ALPS.
 
Introduction
 
Cell death mediated by the TNF receptor family member Fas
(TNFRSF6 and CD95) is required for normal lymphocyte
homeostasis and peripheral immune tolerance (Lenardo et al.,
1999). In Fas-deficient 
 
lpr/lpr
 
 mice and patients with germ-line
dominant-negative Fas mutations and the autoimmune lympho-
proliferative syndrome (ALPS), abnormal lymphocytes accumu-
late and systemic autoimmunity often ensues (Fisher et al.,
1995; Siegel et al., 2000a). Ligation of Fas by Fas ligand
(FasL) or agonistic antibodies triggers the rapid recruitment of
the death domain (DD) of the adaptor protein FADD to the
homologous DD of Fas, followed by the recruitment of pro-
caspase-8 and -10 through the interaction of death-effector
domains in the amino termini of FADD and the procaspases.
The resulting Fas/FADD/caspase complex is termed the death-
inducing signaling complex (DISC; Kischkel et al., 1995).
Studies of knockout mice and mutant cell lines established that
the DISC is essential for Fas apoptosis signaling in lymphocytes
(Varfolomeev et al., 1998; Zhang et al., 1998). DISC assembly
differs between cell types in ways that influence the efficiency
of Fas signaling. In “type I” cell lines and restimulated primary
T cells, the DISC forms efficiently, and apoptosis can be induced
with bivalent anti-Fas stimuli without additional cross-linking
(Scaffidi et al., 1998). This may be due to the constitutive asso-
ciation of Fas in these cells with glycosphingolipid-enriched
detergent-resistant membrane microdomains termed lipid rafts
(Muppidi and Siegel, 2004). However, in “type II” cell lines
and recently activated primary T cells, the DISC is formed
inefficiently, hypercrosslinking of Fas is necessary to induce
apoptosis, and Fas is not associated with lipid rafts.
Recent work has identified a series of signaling events
that follow Fas binding to FasL or agonistic antibodies. In cell
lysates, SDS-stable high-molecular weight oligomers of receptors
can be seen to form in seconds, followed by maximal recruit-
ment of FADD and caspase-8 within 15 min (Kischkel et al.,
1995). Receptor cap structures and internalization of the receptor
have been observed 15 min to 1 h after receptor triggering
depending on the experimental system (Cremesti et al., 2001;
Algeciras-Schimnich et al., 2002). However, cap formation
was found to be dependent on caspase activation, and is there-
fore not a proximal event in receptor signaling. Of greater
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interest are events that occur before and are required for pro-
caspase activation.
How procaspase-8 and 10 are activated after recruitment
to the cytoplasmic domain of Fas is not known. It is thought
that DISC formation promotes the activation of caspase-8.
Forced caspase-8 oligomerization, even in the absence of
FADD, is sufficient for its enzymatic activation (Martin et al.,
1998; Muzio et al., 1998). More recently, it has been shown
that in vitro
 
,
 
 caspase-8 enzymatic activation can occur even
without cleavage of the proenzyme into its active form (Yang
et al., 1998; Boatright et al., 2003; Donepudi et al., 2003). We
have found that Fas itself can exist in an oligomerized state be-
fore ligand binding (Siegel et al., 2000b). This finding predicts
that FasL or multivalent antibody binding may trigger signal-
ing through rearrangement of receptor chains or formation of
higher order receptor structures.
Here, we examine consequences of Fas signaling with
high resolution confocal microscopy. We find that Fas ligation
by agonistic antibody or ligand results in the formation of mi-
croscopically visible surface receptor microclusters before cas-
pase enzymatic activity. Fas mutations associated with ALPS
that impair formation of these structures do not allow full cas-
pase-8 activation and apoptosis induction.
 
Results
 
Formation of signaling protein 
oligomerization transduction structures 
(SPOTS) is an early event following Fas 
receptor ligation
 
To follow the subcellular localization of endogenous Fas
during signaling, we treated the lymphoblastoid B cell line
SKW6.4, which expresses relatively high levels of Fas, with
anti-Fas mAb or FasL at 37
 
 
 
C, and then fixed and stained the
cells with a secondary antibody to reveal the pattern of Fas
subcellular localization. In these cells, we observed small
spotlike foci of staining beginning 15 min after receptor liga-
tion, followed by caplike structures visible after 30 min (Fig.
1). The small foci measured 0.3–0.5 
 
 
 
m in size. As we will
show that these foci represent oligomerized receptors and re-
quire signaling protein recruitment for their formation, we
will refer to them as SPOTS. Interestingly, in the presence of
the caspase inhibitor zVAD-fmk, cells with SPOTS were
readily seen, but cells with capped Fas were rarely seen. To
determine whether or not SPOTS form before internalization
of the receptor, we used a double-labeling strategy to specif-
ically mark surface Fas complexes. As can be seen in Fig. 2
A, in SKW6.4 cells treated for 60 min with anti-Fas, Fas
complexes were largely internalized. FACS staining experi-
ments confirmed that surface receptor levels were signifi-
cantly reduced in these cells (Fig. 2 B). However, in the
presence of zVAD-fmk, surface-labeled SPOTS predomi-
nated, and FACS staining of zVAD-treated cells revealed
normal or even increased levels of surface Fas. Thus, forma-
tion of SPOTS occurs at the plasma membrane during the
same time frame that the Fas signaling complex assembles at
the cytoplasmic tail of the receptor.
Lipid raft microdomains can facilitate oligomerization of
receptors into larger signaling complexes. Therefore, we inves-
tigated the relationship between SPOTS and lipid rafts in dif-
ferent cell types. When lipid rafts were imaged with cholera-
toxin B after Fas receptor cross-linking, we observed that lipid
raft microdomains coclustered with SPOTS in type I cells (Fig.
3). In type II cells, SPOTS formed without coclustering of the
cholera-toxin label, suggesting that lipid rafts remained dif-
fusely distributed on the plasma membrane. This data agrees
with previous findings that Fas signaling in type-II cells is in-
dependent of lipid rafts (Muppidi and Siegel, 2004).
 
SPOTS formation requires recruitment 
of FADD to the Fas DD
 
To examine if the changes we observed in the subcellular local-
ization of Fas occurred during signaling in live cells, we used
confocal microscopy to study the localization of Fas-YFP fu-
sion proteins before and after receptor triggering by FasL or
agonistic antibodies. In transiently transfected Cos cells, Fas-
Figure 1. Distinct caspase-dependent and -independent morphological
stages in Fas signaling. Immunostaining of Fas performed after the follow-
ing treatments at 37 C: (A) isotype control; (B) 15-min anti-Fas; (C) 30-min
anti-Fas; (D) 60-min anti-Fas with 60-min pretreatment with 50  M zVAD-
fmk; (E) 60-min Anti-FLAG control; (F) 60-min FLAG-FasL and anti-FLAG.
For each panel, a low-power mid-cell confocal section and a high power
reconstruction of a z-stack of a representative cell is shown. Results are
representative of three independent experiments. 
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YFP fusion proteins were distributed diffusely on the plasma
membrane in most cells. Some cells exhibited additional intra-
cellular fluorescence in patterns consistent with Golgi complex
localization. After addition of agonistic anti-Fas antibody or
FasL, intense foci of Fas-YFP fluorescence appeared at the
plasma membrane within 8–15 min, peaking at 60 min (Fig. 4
A and Video 1, available at http://www.jcb.org/cgi/content/
full/jcb.200406101/DC1). These foci appeared before changes
in cell shape or nuclear morphology characteristic of apoptosis.
Three-dimensional reconstruction of confocal z-sections of
these cells confirmed the surface localization of SPOTS (Fig. 4
A). As with endogenous Fas, caspase inhibition did not block
formation of SPOTS. In contrast, deletion of the Fas DD al-
most completely blocked the formation of SPOTS. We ob-
served quantitatively similar results in SKW6.4 cells trans-
fected with Fas-YFP, including the dependence of SPOTS
formation on the Fas DD (Fig. 4 B). FasL was somewhat less
efficient at inducing SPOTS despite equivalent maximal levels
of apoptosis induced by FasL and anti-Fas mAb (Fig. 4, B and
C). These data indicate that Fas SPOTS form in living cells af-
Figure 2. Capping and internalization but not SPOTS depend on caspase activity. (A) SKW 6.4 cells were stimulated as shown and then labeled for surface
and internalized Fas as described in the Flow cytometric quantitation of Fas surface levels section of Materials and methods. The top panels show Alexa-
488 staining of surface Fas in green, the middle panels show surface and intracellular staining by Alexa-594 in red, and the bottom panels show com-
bined fluorescence with colocalized proteins staining in yellow. Separate experiments showed that the two anti-IgG secondary antisera did not cross-block
(not depicted). Each panel shows medium and high power magnifications from left to right. Bars: (left) 5  m; (right) 1  m. (B) Flow cytometric quantitation
of surface Fas expression after similar treatment of SKW 6.4 cells. Numbers are derived from the geometric mean fluorescence normalized a value of 100
for untreated cells.
Figure 3. Differential coclustering of SPOTS
with lipid rafts in type I and type II cells. Two-
color fluorescence microscopy of cells treated
with anti-Fas in the presence of Alexa-594–
labeled cholera toxin B (red) for 30 min and
then stained for Fas with anti-IgG3 Alexa-488
(green). Arrowheads mark examples of mem-
brane areas with bright patches of Fas and
the CTB staining at the same location. 
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ter antibody and ligand stimulation and are not simply the re-
sult of passive antibody-mediated receptor clustering.
When transfected into Jurkat cells, Fas-YFP also formed
SPOTS after receptor ligation, followed by receptor internal-
ization, although with less prominent cap formation. An ex-
ample of time-lapse images from a typical transfectant is
shown in Fig. 5 and Video 2 (available at http://www.jcb.org/
cgi/content/full/jcb.200406101/DC1). To determine whether
or not FADD and caspase-8 are required for formation of
SPOTS, we transfected wild-type Fas-YFP into mutant Jur-
kat cells that have been shown to lack FADD or caspase-8
and are completely resistant to Fas-induced apoptosis (Juo
et al., 1998). As shown in Table I, FADD-deficient Jurkat
cells as well as wild-type Jurkat cells transfected with a DD-
deficient truncated Fas-YFP were almost completely defi-
cient in SPOTS formation. Caspase-8–deficient Jurkat cells
were partially deficient in SPOTS formation. As in other
cell types, zVAD-fmk treatment of wild-type cells did not af-
fect SPOTS formation although apoptosis was completely
inhibited.
To determine whether receptor internalization was down-
stream or coincident with formation of SPOTS during signal-
ing in live cells, we developed a flow cytometric assay to mea-
sure surface levels of Fas-YFP fusion protein before and after
addition of agonistic antibodies. Fas-YFP internalization was
slower than endogenous Fas in SKW 6.4, with maximal de-
crease in surface staining after 4 h of anti-Fas or FasL treat-
ment. Jurkat cells transfected with DD-deleted Fas failed to in-
Figure 4. Redistribution of wild-type and
mutant Fas-YFP fusion proteins after anti-Fas
treatment. (A) Cos-7 cells transiently trans-
fected with the indicated Fas-YFP fusion proteins
were treated with 1  g/ml of APO-1 and 0.1
 g/ml of protein A for 30 min at 37 C and
z-stack images of live cells were acquired by
confocal microscopy. The top panels show
vertical maximum intensity projections of the
stacks and the bottom panels show a mid-cell
section of the same stack rotated 90 . The
numbers underneath each panel are the per-
centage of cells exhibiting receptor SPOTS
after 30 min of anti-Fas mAb treatment. (B)
Comparison of SPOTS induced by FasL and
anti-Fas. SKW6.4 cells were transiently trans-
fected with the indicated Fas-YFP fusion protein
constructs and treated with either anti-Fas
mAb or FasL-FLAG with anti-FLAG cross-linking
as described in the Patients, cell lines, plasmids,
and reagents section in Materials and methods.
After 60 min at 37 C, live cells were scored
for the presence of SPOTS or caps by a blinded
observer in duplicate. The numbers are the
average   SEM for each condition. Without
anti-FLAG cross-linking  10% SPOTS or caps
were observed (not depicted). (C) Cell death
induced in SKW6.4 the same preparations of
FasL and anti-Fas as in B. Cell death was mea-
sured at 6 h by annexin/PI staining. 
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ternalize the receptor after anti-Fas or FasL treatment (Fig. 6
A). As expected, FADD and caspase-8–deficient Jurkat cells
were almost completely resistant to Fas-induced apoptosis.
FADD-deficient Jurkat cells also failed to internalize Fas-YFP
after receptor ligation and caspase-8–deficient Jurkat cells had
partial inhibition of receptor downmodulation (Table I). Cas-
pase inhibition with zVADfmk also partially blocked Fas-YFP
internalization, despite having little effect on formation of
SPOTS (Table I and Fig. 6 A). Thus, as with endogenous Fas,
downmodulation of Fas-YFP in living cells is downstream of
SPOTS formation and dependent on caspase activity. Receptor
endocytosis appeared to be clatharin independent because sur-
face downmodulation was not blocked by a dominant-negative
dynamin construct (unpublished data).
Figure 5. Kinetics of SPOTS formation and internalization of Fas-YFP fusion proteins. (A) Selected frames from a confocal time series of Jurkat cells trans-
fected with wild-type Fas-YFP fusion protein and treated with anti-Fas at the indicated time point (minutes:seconds). Midsection confocal images of the
whole cell are shown in the top panels, and an enlarged view of a portion of the plasma membrane is shown at each time point with the intracellular (i)
and extracellular (e) compartments in the first frame of each row.
 
Table I. 
 
Quantitation of Fas-YFP fusion protein clustering and downmodulation in live Jurkat T cells
Cell type
(Jurkat derivative)
Fas-YFP fusion
construct Treatment
Percentage
of SPOTS or
caps 
 
 
 
 SD
Surface Fas
downmodulation
(% control)
Fas-induced
apoptosis
(% control)
 
WT WT Anti-Fas (100) (100) (100)
WT WT Anti-Fas 
 
  
 
zVAD-fmk 96.4 38.1
 
 
 
0
WT Del DD Anti-Fas 16.1 11.9 3.3
WT T225K Anti-Fas 21.1
 
 
 
03 3
FADD deficient WT Anti-Fas 15.7
 
 
 
0 2.4
Caspase-8 deficient WT Anti-Fas 44.3 23.8 5.5
vFLIP line WT Anti-Fas 33.4 3.1 3.4
vFLIP control WT Anti-Fas (100) (100) (100)
Bcl-x line WT Anti-Fas 101.8 57.1 41
Bcl-x control WT Anti-Fas (100) (100) (100)
 
Cells were treated for 60 min with crosslinked anti-Fas APO-1-3 mAb and microscopically scored for receptor clustering with fluorescence microscopy by a blinded
observer. Numbers represent the average and SD of at least two independent experiments. Specific Fas downmodulation was calculated from the median channel
fluorescence data shown in Fig. 6. Fas-induced apoptosis was calculated from annexin and PI staining and normalized to the percent specific death in the appropriate
control cells. 
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Because caspase inhibitors blocked both apoptosis and
receptor downmodulation, it was possible that receptor down-
modulation was a consequence of effector caspase activation
during apoptosis. To examine this possibility, we used Jurkat
cells stably transfected with the antiapoptotic inhibitor Bcl-xL,
which blocks mitochondrial amplification of the apoptosis sig-
nal and is required in Jurkat cells for efficient Fas-mediated
apoptosis. Bcl-xL overexpression does not affect recruitment
and activation of caspase-8 at the DISC (Stegh et al., 2002).
Fas-YFP in Bcl-xL transfectants was equally able to form
SPOTS, and Fas downmodulation was 57% of vector-trans-
fected cells (Table I and Fig. 6 B). In contrast, in a Jurkat line
overexpressing the viral FLIP MC159, a proximal blocker of
caspase-8 recruitment and activation in the DISC, both SPOTS
formation and receptor downmodulation were more severely
impaired (Fig. 6 B and Table I). These findings suggest that
Fas can be internalized after SPOTS formation without activa-
tion of post-mitochondrial effector caspases.
 
ALPS mutations block formation of 
SPOTS and caspase-8 activation 
through distinct mechanisms
 
Most ALPS-associated Fas mutations in the DD fail to bind to
FADD, resulting in dominant inhibition of DISC formation
(Martin et al., 1999; Vaishnaw et al., 1999). However, unlike
all other previously described Fas DD mutants, the Fas T225K
mutation from ALPS kindred #27 retained the ability to inter-
act with FADD in GST pull-down and coimmunoprecipitation
assays, although FADD binding was weaker than for wild-type
Fas (Fig. 7 A and not depicted). Mutation of the same amino
Figure 6. Dependence of Fas-YFP receptor internalization on the Fas DD
and caspase activity. (A) FACS analysis of Fas-YFP internalization in trans-
fected wild-type Jurkat cells after anti-Fas (top) or FasL (bottom) treatment for
2 h. The dashed histograms represent levels of Fas-YFP surface expression
before treatment and the solid lines represent levels after treatment. The
numbers are the change in geometric mean channel fluorescence between
treated and untreated cells for each transfectant, with positive numbers
indicating decreased fluorescence and negative numbers an increase after
treatment. Populations were gated on viable cells expressing the Fas-YFP
fusion protein. The fusion protein constructs are indicated above each panel.
(B) FACS analysis of internalization of WT Fas-YFP fusion proteins in Jurkat
clones stably overexpressing Bcl-x and v-FLIP and a control clone trans-
fected with the drug-resistance plasmid alone. Results are shown as in A.
Figure 7. ALPS-associated Fas mutations block SPOTS formation by
distinct mechanisms. (A) GST pull-down assay with the indicated mutant
Fas DD proteins or GST alone, and 
35S-labeled FADD, was performed as
described previously (Martin et al., 1999). Vertical black lines divide
lanes taken from the same blot. (B) Signaling complex formation and
caspase-8 processing in EBV lines from selected Fas mutant ALPS patients
and zVAD-fmk treated normal donor-derived cells. EBV cell lines were
stimulated with 1  g/ml of APO-1 anti-Fas mAb for 10 min or the times
indicated, and the DISC was immunoprecipitated as described previously
(Martin et al., 1999). Caspase-8 cleavage in cell lysates are shown in
the bottom panel. Arrowheads denote protein fragments of interest and
open circles denote background bands. Vertical black lines divide lanes
taken from the same blot. (C) DEVDase effector caspase assay of lysates
from EBV-transformed cell lines or ALPS patient EBV cell lines heterozygous
for the indicated Fas mutations. Cells were treated for 1 h with 1  g/ml
of APO-1 anti-Fas mAb. Assays were performed as described previously
(Martin et al., 1999). Values are the fluorescence of treated minus con-
trol for each cell line in arbitrary fluorescence units. Error bars represent
the SEM for triplicate measurements. 
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acid to proline in the T225P mutant from another ALPS family
completely abrogated FADD binding and globally perturbed
DD folding (Fig. 7 A; Martin et al., 1999). However, the Fas
T225K DD retained a normal overall structure (unpublished
data). Analysis of DISC formation in patient-derived cell lines
harboring the T225K mutant showed normal recruitment of
FADD and procaspase-8 after anti-Fas stimulation, whereas
cells from ALPS patients harboring the non-FADD binding
R234Q mutation or other Fas DD mutations demonstrated se-
vere defects in DISC formation (Fig. 7 B; Martin et al., 1999).
Despite normal DISC formation, cells harboring the T225K
mutation produced no detectable fully processed caspase-8 in
cell lysates even after prolonged Fas stimulation (Fig. 7 B).
This pattern was similar to wild-type cells treated with anti-Fas
in the presence of zVAD-fmk (Fig. 7 B). Apoptosis, as mea-
sured by effector caspase activation, was impaired in cell lines
derived from patients heterozygous for the Fas T225K muta-
tion, but was slightly higher than that in cell lines from patients
harboring non FADD-binding DD mutations (Fig. 7 C). This
finding is consistent with data showing that FasT225K is de-
fective when transfected alone and is a weak dominant-nega-
tive inhibitor of apoptosis triggered by wild-type Fas (Jackson
et al., 1999).
To correlate these biochemical abnormalities in Fas sig-
naling with the subcellular localization of Fas, we transfected
Fas-YFP fusion proteins containing non-FADD binding and
the T225K FADD-binding Fas mutations into COS-7 cells and
observed the morphology of receptor fluorescence in live cells
after anti-Fas antibody treatment. Interestingly, cells trans-
fected with either the non-FADD–binding D244V mutant or
the T225K mutant failed to form SPOTS (Fig. 8 A). Similar re-
sults were seen with Jurkat cells transfected with FasT225K-
YFP (Table I). Immunofluorescence analysis of endogenous
Fas in EBV-transformed lymphoblastoid cell lines from ALPS
patients bearing these same two mutations revealed an almost
complete defect in formation of SPOTS in cells harboring het-
erozygous FasD244V mutations after treatment with anti-Fas
mAb (Fig. 8 B). Cells heterozygous for the T225K Fas muta-
tion exhibited a partial defect in formation of SPOTS as well as
defects in receptor downmodulation and cap formation after re-
ceptor cross-linking (Fig. 8, B and C), although these defects
were not as severe as in cells harboring non FADD-binding Fas
mutations. Thus, the defect in caspase-8 processing in the
DISC of heterozygous Fas T225K cells specifically impairs
FAS SPOTS formation and receptor internalization down-
stream of FADD recruitment.
 
Discussion
 
Fas apoptosis signaling depends on activation of procaspase-8
that is directly recruited to the cytoplasmic tail of the receptor
through the adaptor protein FADD. Oligomerization of cas-
pase-8 can activate its proteolytic activity even in its uncleaved
pro-enzyme state (Yang et al., 1998; Boatright et al., 2003;
Figure 8. ALPS Fas mutations and patient cells display defective SPOTS formation and receptor downmodulation. (A) Cos-7 cells transiently transfected
with the indicated Fas-YFP fusion proteins were treated with 1  g/ml of APO-1 and 0.1  g/ml of protein A for 30 min at 37 C and z-stack images of live
cells were acquired by confocal microscopy and shown as in Fig. 2. (B) EBV-transformed B cell lines from healthy donors or patients with the indicated
mutations were treated with anti-Fas for 1 h, stained for Fas as described in Materials and methods, and visually scored for receptor surface clustering or
capping, with the total percentage of capped or clustered Fas given below each panel. Mid-cell confocal sections and three-dimensional reconstructions
of representative cells are shown for anti-Fas–treated (bottom) or untreated (top) cells. Insets show three-dimensional reconstruction of z-stack images for a
representative cell in each condition. The numbers below each panel represent the percentage of cells exhibiting SPOTS or caps after anti-Fas treatment.
(C) Quantitation of surface Fas after treatment of the indicated EBV patient-derived cells with anti-Fas and normal cells treated with or without the zVAD-fmk
caspase inhibitor. 
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Donepudi et al., 2003). Thus, it is critical to understand how li-
gation of Fas and other death receptors activate this apical en-
zyme in the receptor-induced apoptosis pathway. Our data
suggest that formation of SPOTS may promote caspase-8 acti-
vation in receptor signaling complexes through aggregation of
receptors and associated signaling molecules into large micro-
scopically visible surface clusters. Given the surface area of 23
nm
 
2
 
 for the structurally related TNF/TNFR complex (Banner et
al., 1993), a large number of trimers could occupy a circular
membrane patch with a diameter of 300 nm, the size of the
smallest clusters we were able to visualize by confocal micros-
copy. We previously reported that Fas and other TNF receptor
family members can self-associate at the molecular level in
preassociated complexes before ligand binding (Chan et al.,
2000; Siegel et al., 2000b). These molecular complexes are
likely to contain fewer receptor chains than SPOTS, as the
same cells exhibiting receptor self-association by techniques
such as coimmunoprecipitation and fluorescence resonance en-
ergy transfer in the absence of ligand exhibited a diffuse pat-
tern of receptor expression on the membrane with very few
SPOTS (
 
 
 
10% of cells).
Formation of Fas SPOTS is dependent on recruitment of
the adaptor protein FADD to the DD in the cytoplasmic tail of
the Fas receptor. Cells harboring Fas mutations that fail to re-
cruit FADD, or FADD-deficient cells, were completely un-
able to form SPOTS, demonstrating a critical requirement for
FADD in this process. In other work, we have found that
FADD self-association through a conserved short peptide motif
is required for Fas signaling and the formation of SPOTS
(unpublished data). Together, these results define a role for
SPOTS in amplifying Fas-mediated signals through homo-
philic adaptor protein interactions. Whether or not other
TNF-family receptors similarly form SPOTS during signaling
is not known. Interestingly, in contrast to Fas, which directly
recruits FADD at the plasma membrane, the DISC of TNFR1
has been recently reported to assemble only after receptor in-
ternalization, illustrating diversity of signaling mechanisms
within the death receptor family (Schneider-Brachert et al.,
2004). Unlike other previously described Fas mutations, the
Fas T225K mutation was able to directly interact with FADD
yet did not support formation of SPOTS. The non-FADD–
binding ALPS-associated Fas mutations block SPOTS forma-
tion indirectly by preventing efficient FADD recruitment to the
DISC. Residue Thr 225 of the Fas DD is located on the surface
between the 
 
 
 
-1 and 
 
 
 
-2 helices, away from the Fas/FADD in-
terface localized to 
 
 
 
-3. As assessed by NMR, the overall fold-
ing of the Fas T225K DD was preserved, whereas the T225P
mutation significantly disrupted folding of the DD and abro-
gated FADD binding (Martin et al., 1999). This result suggests
that the T225 residue is not itself directly involved in FADD
binding. T225 could be involved in Fas–Fas interactions, but
we have found that self-interaction through the DD of T225K
mutant Fas is maintained (unpublished data). Instead, lower af-
finity for FADD or altered quaternary structure of signaling
complexes containing the Fas T225K mutation may not allow
for FADD lateral interactions, precluding the formation of
SPOTS and caspase-8 processing. Although in vitro the cas-
pase-8 proenzyme can become enzymatically active at high
concentrations (Boatright et al., 2003), the data with the T225K
mutation suggest that the function of SPOTS is to allow cas-
pase-8 to concentrate at the plasma membrane at sufficiently
high levels to achieve full enzymatic activation in vivo.
In contrast to deficiencies of signaling proteins, we found
that caspase inhibitors had only modest effects on SPOTS but
almost completely blocked Fas capping and internalization. A
previous paper noted that zVAD-fmk blocked ligand-induced
receptor clustering (Algeciras-Schimnich et al., 2002). How-
ever, the morphology of what was termed clustering in that pa-
per more closely resembles what we describe here as capping
and is thus a later step in signaling than SPOTS. Our double-
labeling experiments show that zVAD-fmk treatment allows
SPOTS formation but prevents receptor internalization. Thus it
is likely that SPOTS result from protein–protein interactions
and other cellular events that are independent of caspase enzy-
matic activity. The formation of SDS-stable microaggregates
of Fas have also been reported to be an almost instantaneous
result of receptor ligation and are independent of caspase activ-
ity (Algeciras-Schimnich et al., 2002). Because these aggre-
gates can be observed in as little as 1 s after addition of anti-Fas
in contrast to the minimum of 5–10 min for SPOTS formation
in vivo it appears SPOTS are a later event than SDS-stable mi-
croaggregates.
Fas-induced receptor capping has also been associated
with ceramide production (Grassme et al., 2001). Because cer-
amide production has been shown to be blocked by caspase in-
hibition (Cock et al., 1998), it is likely that ceramide produc-
tion is downstream of SPOTS formation in the Fas signaling
pathway. The role that receptor internalization may play in an
irreversible process such as apoptosis is not clear. However, it
should be noted that other biological outcomes, such as prolif-
eration and lymphocyte activation, have also been associated
with death receptor signaling, and receptor internalization may
be a way to terminate these signals. What effect caspase inhibi-
tion has on the internalization of other receptor classes is not
known.
Our findings with the Fas T225K mutation are the first
description of a pathogenic receptor mutation that specifically
impairs receptor aggregation during signaling. Additional mu-
tations in Fas or other TNFR-family receptors may also use this
mechanism of disease pathogenesis. As SPOTS appear to be a
proximal manifestation of receptor signaling that are required
for signaling to proceed, inhibiting formation of SPOTS may
be a therapeutic target for strategies designed to modulate sig-
naling by the many clinically important members of the TNF-
receptor superfamily.
 
Materials and methods
 
Patients, cell lines, plasmids, and reagents
 
ALPS patients and their specimens were studied with informed consent ac-
cording to research protocols approved by National Institutes of Health
(NIH) Institutional Review Boards. They and their specific Fas mutations
were described previously (Jackson et al., 1999). EBV transformed cell
lines from ALPS patients’ peripheral blood B cells were derived by R.
Fischer (National Human Genome Research Institute, NIH, Bethesda,
MD), as described previously (Jackson et al., 1999). The cell lines Jurkat 
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A3 (wild-type), Jurkat I9.2 (caspase-8 deficient), and Jurkat I2.1 (FADD de-
ficient) were obtained from American Type Culture Collection. Cos-7 cells
were a gift from A. Kenworthy (National Institute of Child Health and Hu-
man Development, NIH, Bethesda, MD). HA-Fas-GFP and YFP fusion pro-
tein vectors were constructed as previously described (Siegel et al.,
2000b), using the pEGFPN1 and pEYFPN1 vectors (CLONTECH Labora-
tories, Inc.) and vectors obtained from R. Tsien (University of California,
San Diego, San Diego, CA). Mutations were created by site-directed mu-
tagenesis (quickchange protocol; Stratagene) and confirmed by sequenc-
ing. The MC159 and bcl-x–transfected Jurkat lines were a gift from D. Bol-
ton (NIH, Bethesda, MD). The FLAG-FasL plasmid was a gift from G.
Screaton (Oxford University, Oxford, UK), and protein was made by
transfecting 293T cells in 20-cm cell culture dishes. After an overnight in-
cubation, the culture medium was changed to CHO-S-SFM II medium (Invit-
rogen). 4 d later, the supernatant from the transfected cells was harvested,
filtered to remove any debris, and aliquoted for storage at 
 
 
 
80
 
 
 
C. Cos
cells transfected in coverslip dishes were transfected with 1 
 
 
 
g of each
plasmid using the FuGene transfection reagent (Roche Molecular Biochem-
icals). 1–2 
 
 
 
 10
 
7
 
 Jurkat cells were transfected using a BTX electroporator
as described previously (Martin et al., 1999). Anti-Fas APO-1-3 was pur-
chased from Kamiya Biochemicals, and Alexa-conjugated secondary anti-
bodies were purchased from Molecular Probes. For cell staining, all mAbs
and secondary reagents were used at 1 
 
 
 
g/ml. ZVAD-fmk was purchased
from Enzyme Systems Products.
 
Immunofluorescence and imaging
 
For live cell imaging, transfected Cos cells were grown on coverslip cham-
bers (Lab-Tek), and Jurkat, H9, or SKW 6.4 cells were added to coverslips
coated with poly-
 
L
 
-lysine immediately before imaging. Samples were
heated to 37
 
 
 
 and APO-1-3 anti-Fas mAb (1 
 
 
 
g/ml with 0.1 
 
 
 
g/ml of
protein-A) or FLAG-FasL (1:20 dilution of culture supernatant with 1 
 
 
 
g/ml
anti-FLAG) was added directly to the cells. For staining of fixed cells, cells
were treated with antibodies or FasL at 37
 
 
 
 for the indicated amounts of
time and adhered to poly-
 
L
 
-lysine–coated coverslips for the last 5–15 min
of culture. Cells were then fixed in 100% methanol at 
 
 
 
20
 
 
 
 for 7 min, fol-
lowed by washing and staining with the indicated antibodies and second-
ary reagents in PBS/0.01% Tween-20/0.5% BSA (IFA buffer). Quantita-
tion of receptor clustering was performed by a blinded observer and at
least two counts of 
 
 
 
100 cells each made for every condition in an exper-
iment. Cells with either SPOTS or caps were counted as clustered. Only
those cells with homogeneous membrane staining were counted as non-
clustered. For simultaneous surface and intracellular staining of Fas,
SKW6.4 cells were treated with 1 
 
 
 
g/ml of APO-1 anti-Fas for 1 h at
37
 
 
 
C. Anti-IgG3 Alexa-488 was added for 30 min on ice in FACS buffer
to visualize residual surface Fas. Cells were fixed and permeabilized and
anti-IgG3 Alexa-594 was added to visualize both surface and intracellular
Fas. Images were acquired on a confocal microscope (TCS-NT [Leica];
LSM 510 [Carl Zeiss MicroImaging, Inc.]) with 63 or 100
 
 
 
 objectives. Im-
ages were processed with IMARIS software (Bitplane, A.G.).
 
Flow cytometric quantitation of Fas surface levels
 
Jurkat cells were transiently transfected with wild-type and mutant HA-Fas-
YFP fusion protein vectors as described previously (Martin et al., 1999).
Cells were treated with 1 
 
 
 
g/ml of APO-1 anti-Fas mAb plus 0.1 
 
 
 
g/ml of
protein A or FLAG-FasL at 1:100 dilution and 1 
 
 
 
g/ml anti-FLAG mAb at
37
 
 
 
C for the indicated times. Cells were stained for surface Fas on ice
with 1 
 
 
 
g/ml anti-HA biotin and 1 
 
 
 
g/ml of avidin Alexa-633 (Molecular
Probes). Propidium Iodide negative viable cells positive for transfected
Fas-YFP were gated and Alexa-633 Fas surface staining was quantitated.
Relative fluorescence was calculated from the ratios of mean channel fluo-
rescence of the YFP positive cells. For quantitation of endogenous surface
Fas levels, cells were treated with 1 
 
 
 
g/ml of APO-1-3 for the indicated
amounts of time at 37
 
 
 
C, and then stained with anti-mouse Alexa-488 on
ice before fixation. Control cells were treated with anti-Fas for equal
amounts of time at 4
 
 
 
C for establishing the baseline levels of surface Fas.
Surface Fas levels on viable cells were quantitated as for transfected cells.
 
Online supplemental material
 
Time-lapse confocal microscopy videos illustrating formation of Fas SPOTS
in Fas-YFP–transfected Cos-7 and Jurkat cells are available online. Online
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200406101/DC1.
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